A nurse is reviewing laboratory results of a client who has atrial fibrillation and is taking warfarin. For which of the following results should the nurse notify the provider?

Choice A reason: Applying a new transdermal patch when chest pain is experienced is not a correct instruction, as it may delay the relief of the pain and increase the risk of adverse effects. Transdermal nitroglycerin is a long-acting form of nitrate that is used for the prevention of angina attacks, not for the treatment of acute episodes. The client should use a short-acting form of nitrate, such as sublingual or spray, for the immediate relief of chest pain.

Choice B reason: Applying the transdermal patch in the morning is a correct instruction, as it helps to maintain a steady level of nitrate in the blood throughout the day and prevent angina attacks. Transdermal nitroglycerin has a duration of action of about 12 to 24 hours, depending on the dose and the individual response. The client should apply the patch in the morning and remove it at night, to allow a nitrate-free interval of at least 8 hours and prevent the development of tolerance.

Choice C reason: Applying the transdermal patch in the same location as the previous patch is not a correct instruction, as it may cause skin irritation and reduce the absorption of the medication. Transdermal nitroglycerin should be applied to a clean, dry, and hairless area of the skin, preferably on the chest, upper arm, or back. The client should rotate the application sites and avoid areas that are exposed to heat, moisture, or friction.

Choice D reason: Applying a new transdermal patch once a week is not a correct instruction, as it may not provide adequate protection against angina attacks and increase the risk of rebound angina. Transdermal nitroglycerin should be applied daily, with a nitrate-free interval of at least 8 hours, to maintain a therapeutic level of nitrate in the blood and prevent the loss of efficacy. The client should follow the prescribed dosing schedule and consult the provider before making any changes.

Choice A reason: Ataxia is not a manifestation of digoxin toxicity, as it does not affect the coordination or balance of the client. Ataxia may be caused by other factors, such as cerebellar disorders, alcohol intoxication, or medication interactions.

Choice B reason: Anorexia is a manifestation of digoxin toxicity, as it affects the appetite and digestion of the client. Anorexia may be accompanied by nausea, vomiting, or abdominal pain, which are also signs of digoxin toxicity. Anorexia may lead to weight loss, dehydration, or electrolyte imbalance, which can worsen the condition of the client.

Choice C reason: Photosensitivity is not a manifestation of digoxin toxicity, as it does not affect the skin or the eyes of the client. Photosensitivity may be caused by other factors, such as sun exposure, allergies, or medication interactions.

Choice D reason: Jaundice is not a manifestation of digoxin toxicity, as it does not affect the liver or the bilirubin level of the client. Jaundice may be caused by other factors, such as liver disease, gallstones, or hemolysis.